Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Market Closed - London S.E. Other stock markets 02:30:00 2024-01-16 am EST			5-day change	1st Jan Change
3,866 ^GBX	-.--%		-.--%	+0.21%

Apr. 11	Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	CI
Apr. 09	Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	CI

Dechra Pharmaceuticals : Availability of the 2019 Annual Report

September 04, 2019 at 08:47 am EDT

4 September 2019

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Availability of 2019 Annual Report and Accounts

The 2019 Annual Report and Accounts is now available to view atwww.dechra.com.

The following documents are scheduled to be mailed to registered shareholders of the Company on 16 September 2019:

· 2019 Annual Report and Accounts

· Notice of the 2019 Annual General Meeting; and

· Proxy Form for the 2019 Annual General Meeting.

In accordance with Listing Rule 9.6.1 a copy of each of these documents will be submitted to the National Storage Mechanism and will be available for viewing shortly after posting.

For further information, please contact:

Melanie Hall, Company Secretary

Telephone number: +44 (0) 1606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra 'D' logo are registered trademarks of Dechra Pharmaceuticals PLC.

Attachments

Original document
Permalink

Disclaimer

Dechra Pharmaceuticals plc published this content on 04 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 September 2019 12:46:06 UTC

Latest news about Dechra Pharmaceuticals

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	Apr. 10	CI
Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	Apr. 09	CI
Dechra Group Holdings Limited Appoints Ian David Page as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director	Apr. 09	CI
Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director	Apr. 09	CI
Stocks slump as Fed rate cut hope dwindles	Jan. 17	AN
Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover	Jan. 17	MT
EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase	Jan. 16	MT
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-World Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 (Ex Investment Companies) Index	Jan. 16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from S&P Global BMI Index	Jan. 16	CI
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC.	Jan. 15	CI
Persimmon to replace outbound FTSE 100 constituent Dechra	Jan. 12	AN
EMEA Morning Briefing : Markets to Track Fresh Middle East Tensions	Jan. 12	DJ
EU clears Dechra Pharmaceuticals takeover by EQT funds	Dec. 27	AN
EQT's Dechra Takeover to Become Effective in Mid-January 2024	Dec. 27	MT
EQT's Takeover of Dechra Pharmaceuticals Gets EU Antitrust Regulator's Nod	Dec. 22	MT
Inchcape to appoint Jerry Buhlmann to chair board of directors from May	Dec. 14	AN
EQT Secures Australian Nod for Dechra Pharmaceuticals Takeover	Nov. 30	MT
FTSE 100 Ends Down, Falling Behind European Peers	Nov. 29	DJ
Hargreaves Lansdown picks Dechra chair Alison Platt as chair	Nov. 29	AN

Chart Dechra Pharmaceuticals

Duration

Period

More charts

Company Profile

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Sector

More about the company

Income Statement Evolution

More financial data